Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 2Lymphoma 2Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Hematologic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1COVID-19 1Advanced Solid Tumors 1Advanced Solid Malignancies 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Rabeprazole × Clear all
NCT05602597 2024-03-06

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Hutchmed

Phase 1 Completed
59 enrolled
Lymphoid

Lymphoma, Recurrence

NCT05571787 2023-02-23

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Hutchmed

Phase 1 Completed
26 enrolled
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡